Antibody Drug Conjugate News and Research

RSS

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics, Inc. and Millennium The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top-line results from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 58 relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) patients.

11 Oct 2010

Seattle Genetics reports SGN-75 phase I clinical trial data

Seattle Genetics, Inc. today reported data from a phase I clinical trial of SGN-75 in patients with non-Hodgkin lymphoma or renal cell carcinoma (RCC). Preliminary results demonstrate tolerability and antitumor activity, including two objective responses in the first 16 patients treated. Dose-escalation is continuing.

11 Oct 2010

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

A new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Seattle Genetics to present SGN-75 phase I data at ESMO Congress

Seattle Genetics, Inc. today announced that preliminary data from a phase I study of SGN-75 in relapsed and refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma will be presented during a poster session at the 35th European Society for Medical Oncology (ESMO) Congress being held October 8-12, 2010 in Milan, Italy.

5 Oct 2010

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.

27 Sep 2010

Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB

Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.

20 Sep 2010

Genmab announces update in corporate strategy

Genmab A/S announced today an update to its corporate strategy. Today's strategy update represents a new beginning for Genmab where we acknowledge our successes and learn from our mistakes.

14 Sep 2010

Genmab, Seattle Genetics enter ADC research collaboration agreement

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into an antibody-drug conjugate (ADC) research collaboration agreement.

14 Sep 2010

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology.

3 Sep 2010

Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.

2 Sep 2010

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

In its review of the BLA, the FDA stated the T-DM1 trials did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population.

27 Aug 2010

Seattle Genetics, Genentech expand antibody-drug conjugate collaboration

Seattle Genetics, Inc. announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group. Under the expanded agreement, Genentech will pay an upfront fee of $12 million for rights to utilize Seattle Genetics' ADC technology with additional antigens to be named by Genentech.

12 Aug 2010

Progenics second-quarter total revenue decreases to $2.3 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the second quarter and six months ended June 30, 2010.

9 Aug 2010

Chemed second-quarter consolidated revenues increase 6.7% to $315.0 million

Chemed Corporation, which operates VITAS Healthcare Corporation, the nation's largest provider of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2010, versus the comparable prior-year period.

29 Jul 2010

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

20 Jul 2010

Early knowledge of HCC response to TACE determines treatment success: Research article

Early knowledge of hepatocellular carcinoma response to transcatheter arterial chemoembolization is crucial for determining treatment success, timing of repeat treatment, and patient prognosis. Currently, magnetic resonance imaging is used 1-3 mo after treatment to evaluate anatomical tumor response, based upon changes in tumor size and contrast-agent enhancement. Alternatively, diffusion-weighted imaging can be used as a functional imaging technique to depict thermally induced motion of water molecules.

9 Jul 2010

CompuMed secures extended contracts with Oklahoma and Arizona's departments of corrections

CompuMed, Inc., a medical informatics and telemedicine services company, has secured extended contracts to provide its signature CardioGram™ electrocardiogram (ECG) remote interpretation systems and over-read services for the Oklahoma Department of Corrections (OKDOC) and Arizona Department of Corrections (ADC) at selected facilities throughout both states. The OKDOC rents 21 CardioGram systems, and the ADC owns 45 CardioGram systems.

8 Jul 2010

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.

7 Jul 2010

Zilog launches ZMOTION Detection and Control solutions

Zilog, an IXYS company, and a trusted supplier of application specific, embedded micro controller (MCU) system-on-chip (SoC) solutions for industrial and consumer markets, today introduced its latest sensing and control technology for motion detection applications, including intrusion, security alarm industry, customer sensing and lighting control, medical patient monitoring, and other energy management applications.

24 Jun 2010

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma.

16 Jun 2010

Antibody Drug Conjugate News and Research

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics reports SGN-75 phase I clinical trial data

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

Seattle Genetics to present SGN-75 phase I data at ESMO Congress

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB

Genmab announces update in corporate strategy

Genmab, Seattle Genetics enter ADC research collaboration agreement

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

Seattle Genetics, Genentech expand antibody-drug conjugate collaboration

Progenics second-quarter total revenue decreases to $2.3 million

Chemed second-quarter consolidated revenues increase 6.7% to $315.0 million

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Early knowledge of HCC response to TACE determines treatment success: Research article

CompuMed secures extended contracts with Oklahoma and Arizona's departments of corrections

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Zilog launches ZMOTION Detection and Control solutions

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunology eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News